Jul 05, 2016
Biogen and AbbVie have announced that the European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for treating adult patients with relapsing forms of multiple sclerosis (RMS). ZINBRYTA is a once-monthly, subcutaneous, self-administered injection.
Professor Gavin Giovannoni, Chair of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry, said: “Clinical data showed ZINBRYTA significantly reduced relapses, 24-week confirmed disability progression and new brain lesions for up to three years compared to AVONEX® (interferon beta-1a) intramuscular injection, providing a valuable new option for people with RMS. ZINBRYTA has an immunomodulatory mechanism of action (MOA) that regulates inflammation without broadly depleting the immune system, and immune cell effects are reversible within six months. This offers an alternative approach to treating multiple sclerosis (MS) and is an important consideration when deciding how to sequence therapies throughout the course of a patient’s disease.”
“With the approval of ZINBRYTA in the European Union, we are providing a much needed treatment option for people living with MS. This is an important part of AbbVie’s ongoing commitment to advancing neuroscience research specifically in the area of MS,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie.European Union Approves Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (daclizumab) for the Treatment of Multiple Sclerosislast edit: 2016-07-21T17:31:52+00:00da